Order Article Reprints

van der Linde R, Gatt PN, Smith S, Fernandez MA, Vaughan L, Blyth E, Curnow J, Brown DA, Tegg E, Sasson SC. Measurable Residual Disease (MRD) by Flow Cytometry in Adult B-Acute Lymphoblastic Leukaemia (B-ALL) and Acute Myeloid Leukaemia (AML): Correlation with Molecular MRD Testing and Clinical Outcome at One Year. Cancers. 2023; 15(20):5064. https://doi.org/10.3390/cancers15205064

van der Linde, Riana, Prudence N. Gatt, Sandy Smith, Marian A. Fernandez, Lachlin Vaughan, Emily Blyth, Jennifer Curnow, David A. Brown, Elizabeth Tegg, and Sarah C. Sasson. 2023. "Measurable Residual Disease (MRD) by Flow Cytometry in Adult B-Acute Lymphoblastic Leukaemia (B-ALL) and Acute Myeloid Leukaemia (AML): Correlation with Molecular MRD Testing and Clinical Outcome at One Year" Cancers 15, no. 20: 5064. https://doi.org/10.3390/cancers15205064

van der Linde, R., Gatt, P. N., Smith, S., Fernandez, M. A., Vaughan, L., Blyth, E., Curnow, J., Brown, D. A., Tegg, E., & Sasson, S. C. (2023). Measurable Residual Disease (MRD) by Flow Cytometry in Adult B-Acute Lymphoblastic Leukaemia (B-ALL) and Acute Myeloid Leukaemia (AML): Correlation with Molecular MRD Testing and Clinical Outcome at One Year. Cancers, 15(20), 5064. https://doi.org/10.3390/cancers15205064